800 million in financing! Did this surgical robot company break the record?

Recently, Italian surgical robot company Medical Microinstruments, Inc. (hereinafter referred to as MMI) officially announced that it has completed a $110 million (about 800 million RMB) Series C financing. It is reported that this round of financing was led by Fidelity Management & Research Company, and the funds raised will be used to help commercialize its surgical robots.

Against the backdrop of the continued rapid development of the medical robotics market, MMI said in a press release that this round of financing marks the largest investment in microsurgical robots ever.

The trend effect is amplified, and the industry is entering a golden period

As the crown jewel of the manufacturing industry chain, the medical robot industry is in a period of rapid growth. According to the MMG research report, the global medical robot market size in 2022 is about US$27.7 billion, and the compound growth rate is expected to be 2.9% in the next six years. By 2029, the market size will exceed US$34 billion.

In this context, surgical robots, as the largest branch of medical robots, have a broader market prospect. Data predicts that by 2028, the number of viable surgical robots in the world is expected to increase from 3 million units per year to 22 million units, achieving an exponential growth of up to 7 times!

Currently, hospitals have an increasing demand for minimally invasive surgery, and surgical robot systems can greatly improve surgical precision, reduce the workload of surgeons, and facilitate patients' postoperative recovery.

It is foreseeable that in the future, surgical robots will enter major hospitals and rewrite the traditional surgical model.

Series C financing helps commercialize surgical robots

At this juncture, this round of financing will undoubtedly inject tremendous momentum into MMI.

As a technology-driven innovation company, MMI is committed to developing a new surgical robot platform, the Symani system, to solve the various problems faced in traditional microsurgery.

The company plans to use the financing to support the commercialization of the Symani system and actively expand into the high-end hospital markets in Europe, America and Asia Pacific. In addition, MMI will also increase its research and development efforts in new technologies and new indications, hoping to use the funds to accelerate the expansion of advanced technology capabilities and global operational capabilities.

Compared with other mainstream surgical robots, the biggest feature of the Symani system is its NanoWrist? ultra-mini robot. With a diameter of only 0.3 mm, NanoWrist is the world's smallest micro- robot arm and can achieve 7 degrees of freedom, far exceeding the range of human hands.

With the help of the ingenious design of the micro-manipulator, the Symani system solves the difficulties in traditional microsurgery, achieves precise reproduction on a microscopic scale, and brings patients an unprecedented refined surgical experience.

Last words

Minimally invasive surgery is a major trend in the development of surgical operations. Compared with open surgery, it has the advantages of less trauma and faster recovery. As medical standards improve, the requirements for surgical precision are getting higher and higher. With the advantages of precise and stable control, surgical robots are expected to be widely popularized in the future.

Public information shows that since its establishment in Pisa, Italy in 2015, MMI has obtained more than 900 million yuan in financing, and even the European Investment Bank (EIB) has provided it with 15 million euros in financial support.

After this round of financing, MMI is expected to enter the harvest period of "deep commercialization". Will this huge amount of money help Symani become the next surgical robot "star"? We will wait and see.